ClinicalTrials.gg
RecruitingNCT07409077Updated Feb 13, 2026

Efficacy of Biofeedback Training for Glaucoma

An interventional study of Biofeedback Training in Glaucoma and Biofeedback Training, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Supportive care

How we know · 2 judgments

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Glaucoma with a site in Canada — 17 open to participants now, 21 under way, 1 of them phase 3. Glaucoma · Canada.

Planned enrollment
29th of 68
70 · median 62
Started
2026
with 4 others
No phase
43 of 85
14 open now
Primary completion
2028-01
later than 17 of 20 live
Registered
83rd of 85
by date
Lead sponsor
7 of 85
University Health Network, Toronto

Among the 85 studies in Glaucoma with a site in Canada, this one is the 29th largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2026, is one of 43 with no phase, reaches primary completion later than 17 of the 20 other live ones, and was the 83rd registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

17 of the 85 studies in Glaucoma with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Glaucoma with a site in Canada, or all of them as a file.
02

Study summary

This randomized controlled clinical trial evaluates the efficacy of visual biofeedback training on visual function and quality of life in individuals with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to irreversible vision loss, including impaired fixation stability, reduced retinal sensitivity, and decreased functional vision. Biofeedback training is a visual rehabilitation technique designed to help patients improve fixation stability and optimize use of remaining visual function by training eye movements toward retinal areas with better sensitivity.

Seventy participants with glaucoma will be randomized to either a biofeedback training intervention group or a control group. Visual function outcomes, including fixation stability, retinal sensitivity, visual acuity, reading speed, contrast sensitivity, and quality of life, will be assessed at baseline and follow-up visits. This study aims to determine whether biofeedback training can improve visual function and quality of life in patients with glaucoma.

Read the detailed description

Glaucoma is a leading cause of irreversible blindness worldwide and is characterized by progressive damage to the optic nerve, resulting in visual field loss, impaired fixation stability, and reduced retinal sensitivity. In advanced stages, patients may develop unstable or eccentric fixation, leading to significant functional visual impairment and reduced quality of life. Current glaucoma treatments primarily aim to control intraocular pressure and do not address the rehabilitation of visual function once damage has occurred.

This prospective, randomized controlled trial is designed to evaluate the efficacy of visual biofeedback training (BT) as a rehabilitation strategy for improving visual function and quality of life in individuals with glaucoma. Biofeedback training is a non-invasive intervention that uses visual and auditory feedback to guide participants in directing their eye movements toward a preferred retinal locus with better sensitivity and stability, thereby optimizing the use of residual vision.

A total of 70 participants with a prior diagnosis of glaucoma will be enrolled and randomized in a 1:1 ratio to either the biofeedback training group (n=35) or a control group (n=35). Participants in the intervention group will undergo five weekly sessions of biofeedback training, each lasting approximately 20 minutes. Participants in the control group will receive standard clinical assessments and will be offered biofeedback training after completion of the control period.

Primary outcome measures include fixation stability and retinal sensitivity assessed using microperimetry, best-corrected visual acuity for distance and near vision, reading speed, and vision-related quality of life. Secondary outcome measures include preferred retinal locus characteristics, contrast sensitivity, oculomotor function (saccades and smooth pursuit), visual field testing, and optical coherence tomography parameters.

Assessments will be conducted at baseline and at follow-up visits, including 9 weeks, 6 months, 1 year, and up to 2 years post-intervention for the treatment group. Data analysis will be conducted using an intention-to-treat approach. This study seeks to determine whether visual biofeedback training can improve functional vision and quality of life in individuals with glaucoma and to explore whether treatment effects vary by age and baseline retinal sensitivity.

03

Conditions studied

  • Glaucoma
  • Biofeedback Training

Browse trials for

Keywords

  • glaucoma
  • biofeedback training
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-95 years old.
  • Glaucoma cases with adequate intraocular pressure control.
  • Presence of paracentral scotomata within two degrees of fixation.
  • Ability to follow instructions for biofeedback training.

Exclusion criteria

Exclusion Criteria:

  • Prior or current low vision rehabilitation treatment.
  • Ocular diseases or severe clinical conditions unrelated to glaucoma
  • Media opacities that prevent reliable microperimetry testing in both eyes.
  • Inability to perform study assessments or follow instructions for biofeedback training.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Biofeedback Training (BT)

    Participants randomized to this arm will receive visual biofeedback training in addition to standard clinical care. The intervention consists of five weekly in-office training sessions, each lasting approximately 20 minutes. During training, participants are guided using visual and auditory feedback to direct eye movements toward a preferred retinal locus with better retinal sensitivity and fixation stability. Visual function and quality of life assessments will be conducted at baseline and at scheduled follow-up visits.

    Other: Biofeedback Training

  • Active comparator
    Control (Delayed Biofeedback Training)

    Participants randomized to this arm will undergo standard clinical assessments without biofeedback training during the initial study period. Visual function and quality of life assessments will be conducted at baseline and at the 9-week follow-up visit. After completion of the control period, participants will be offered biofeedback training as part of standard clinical care.

    Other: Biofeedback Training

Interventions

  • OtherBiofeedback Training

    Visual Biofeedback Training

06

What researchers measure

Primary outcomes

  1. Quality of Life Questionnaire

    Quality of Life using the MAssof 48 questions validated questionnaire

    Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.

  2. Visual acuity

    Distance visual acuity measured with ETDRS charts at 4 meters

    Time frame: Baseline and follow-up visits at 9 weeks, 6 months, 1 year, and 2 years post-intervention

  3. Fixation Stability

    Measured with the MP3 MICROPERIMETER

    Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.

Secondary outcomes

  1. Near Vision

    Measured with the Colenbrander charts at 100% contrast in ETDRS logMAR.

    Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.

  2. Reading speed

    Measured with the MNRead App

    Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.

  3. Contrast Sensitivity

    Measured with the VCTS charts.

    Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.

  4. Retinal Sensitivity

    Measured with the Nidek MP3 microperimeter

    Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • K. Schuster A, Erb C, M. Hoffmann E, Dietlein T, Pfeiffer N. The Diagnosis and Treatment of Glaucoma. Dtsch Ärztebl Int. 2020 Mar;117(13):225-34. 2. Kang JM, Tanna AP. Glaucoma. Med Clin North Am. 2021 May;105(3):493-510. 3. Vingolo EM, Casillo L, Mecarelli G, Limoli PG. Rehabilitative strategies after filtering procedure in glaucoma. Sci Rep. 2022 Oct 7;12(1):16877. 4. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology. 2014 Nov 1;121(11):2081-90. 5. Tomairek RH, Aboud SA, Hassan M, Mohamed AH. Studying the role of 10-2 visual field test in different stages of glaucoma. Eur J Ophthalmol. 2020 Jul;30(4):706-13. 6. Kameda T, Tanabe T, Hangai M, Ojima T, Aikawa H, Yoshimura N. Fixation behavior in advanced stage glaucoma assessed by the MicroPerimeter MP-1. Jpn J Ophthalmol. 2009 Nov;53(6):580-7. 7. Verboschi F, Domanico D, Nebbioso M, Corradetti G, Zaccaria Scalinci S, Vingolo EM. New trends in visual rehabilitation with MP-1 microperimeter biofeedback: optic neural dysfunction. Funct Neurol. 2013;28(4):285-91. 8. Quaranta L, Riva I, Gerardi C, Oddone F, Floriano I, Konstas AGP. Quality of Life in Glaucoma: A Review of the Literature. Adv Ther. 2016;33(6):959-81. 9. Wilson MR, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology. 1998 Nov;105(11):2112-6. 10.Nguyen M. The cost of vision loss and blindness in Canada. 11.Misawa M, Pyatova Y, Sen A, Markowitz M, Markowitz SN, Reber M, et al. Innovative vision rehabilitation method for hemianopsia: Comparing pre- and post audio-luminous biofeedback training for ocular motility improving visual functions and quality of life. Front Neurol. 2023;14:1151736. 12.Daibert-Nido M, Pyatova Y, Markowitz M, Taheri-Shirazi M, Markowitz SN. Post audio-visual

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 23 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 13, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Jan 30, 2028
CompletionEst.
Jun 2028
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409077
Responsible party
Monica Daibert Nido (Dr, University Health Network, Toronto) — Principal investigator
First posted
Feb 13, 2026
Start date
Feb 10, 2026
Primary completion
Jan 30, 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion